Literature DB >> 16146849

Mesenchymal stem cells in stem cell transplant recipients are damaged and remain of host origin.

Jing Wang1, Kaiyan Liu, Dao-Pei Lu.   

Abstract

The aim of this study was to investigate the expansion capacity and origin of bone marrow-derived mesenchymal stem cells (MSCs) in 34 patients who received a sex-mismatched stem cell transplant (SCT). Polymerase chain reaction (PCR) analysis of the amelogenin gene (AMEL) was used to detect donor-derived MSCs. Cultured MSCs were hybridized with fluorescence in situ hybridization (FISH) probes for chromosomes X and Y to distinguish cells of donor origin from those of host origin. The MSCs of 31 of the 34 patients showed confluent stroma, and the MSCs from 24 of these 31 patients were successfully passaged more than 5 times and were able to be used for PCR and FISH analyses. The colony-forming unit-fibroblast, confluence time, and passage numbers of the MSCs and the colony-forming capacity of the hematopoietic progenitor cells of the patients were significantly different from those of 30 healthy control subjects. Flow cytometry results showed that the proportion of CD14(+)CD45(+) cells, which are regarded as monocytes/macrophages, in cultured MSCs (fifth passage) was less than 0.04%. PCR and FISH analyses revealed that the MSC-derived cells in all 24 patients were from the host. In conclusion, the expansion capacity of MSCs in patients who receive an SCT is damaged, and the MSCs originate from the host.

Entities:  

Mesh:

Year:  2005        PMID: 16146849     DOI: 10.1532/IJH97.A10505

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  29 in total

1.  A simple and cost-effective method for preparing DNA from the hard tooth tissue, and its use in polymerase chain reaction amplification of amelogenin gene segment for sex determination in an Indian population.

Authors:  A V Sivagami; A R Rao; U Varshney
Journal:  Forensic Sci Int       Date:  2000-05-15       Impact factor: 2.395

Review 2.  Mesenchymal stem cells: biology and potential clinical uses.

Authors:  R J Deans; A B Moseley
Journal:  Exp Hematol       Date:  2000-08       Impact factor: 3.084

Review 3.  Mesenchymal stem cells: heading into the clinic.

Authors:  O N Koç; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2001-02       Impact factor: 5.483

Review 4.  Regulation of hemopoietic cell growth and development: experimental and clinical studies.

Authors:  T M Dexter
Journal:  Leukemia       Date:  1989-07       Impact factor: 11.528

Review 5.  Toxic effects on the hematopoietic microenvironment.

Authors:  J S Greenberger
Journal:  Exp Hematol       Date:  1991-12       Impact factor: 3.084

Review 6.  Autologous transplantation in acute leukemias, including purging.

Authors:  A K Burnett
Journal:  Curr Opin Oncol       Date:  1990-04       Impact factor: 3.645

7.  Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.

Authors:  E M Horwitz; D J Prockop; L A Fitzpatrick; W W Koo; P L Gordon; M Neel; M Sussman; P Orchard; J C Marx; R E Pyeritz; M K Brenner
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

8.  A human X-Y homologous region encodes "amelogenin".

Authors:  Y Nakahori; O Takenaka; Y Nakagome
Journal:  Genomics       Date:  1991-02       Impact factor: 5.736

9.  Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.

Authors:  D C Betticher; H Huxol; R Müller; B Speck; C Nissen
Journal:  Exp Hematol       Date:  1993-11       Impact factor: 3.084

10.  Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor.

Authors:  D Toksoz; K M Zsebo; K A Smith; S Hu; D Brankow; S V Suggs; F H Martin; D A Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

View more
  9 in total

1.  In vivo Differentiation Potential of Mesenchymal Stem Cells: Prenatal and Postnatal Model Systems.

Authors:  Courtney Quinn; Alan W Flake
Journal:  Transfus Med Hemother       Date:  2008-05-16       Impact factor: 3.747

2.  Bone Marrow-Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality.

Authors:  Elizabeth O Stenger; Raghavan Chinnadurai; Shala Yuan; Marco Garcia; Dalia Arafat; Greg Gibson; Lakshmanan Krishnamurti; Jacques Galipeau
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-26       Impact factor: 5.742

3.  Stromal-derived factor-1 deficiency in the bone marrow of acute myeloid leukemia.

Authors:  Jian Ge; Ruiqin Hou; Quanhua Liu; Rongjia Zhu; Kaiyan Liu
Journal:  Int J Hematol       Date:  2011-05-24       Impact factor: 2.490

4.  Vascular and perivascular niches, but not the osteoblastic niche, are numerically restored following allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia.

Authors:  Liangliang Wu; Wenjian Mo; Yuping Zhang; Ming Zhou; Yumiao Li; Ruiqing Zhou; Shiling Xu; Shiyi Pan; Hui Deng; Ping Mao; Shunqing Wang
Journal:  Int J Hematol       Date:  2017-03-16       Impact factor: 2.490

5.  Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells.

Authors:  Molly Mercedes Ryan; Mihir Patel; Keenan Hogan; Ariel Joy Lipat; Rafaela Scandolara; Rahul Das; Charles Bruker; Jacques Galipeau; Raghavan Chinnadurai
Journal:  Transplant Cell Ther       Date:  2021-02-04

6.  The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes.

Authors:  Zhigang Zhao; Zhenling Wang; Qiubai Li; Weiming Li; Yong You; Ping Zou
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

7.  Mesenchymal stem cells: from experiment to clinic.

Authors:  William R Otto; Nicholas A Wright
Journal:  Fibrogenesis Tissue Repair       Date:  2011-09-08

8.  Human bone marrow-derived mesenchymal stem cells.

Authors:  A Nasef; L Fouillard; A El-Taguri; M Lopez
Journal:  Libyan J Med       Date:  2007-12-01       Impact factor: 1.657

9.  Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected.

Authors:  Liana E Gynn; Elizabeth Anderson; Gareth Robinson; Sarah A Wexler; Gillian Upstill-Goddard; Christine Cox; Jennifer E May
Journal:  Mutagenesis       Date:  2021-11-29       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.